Reports of Practical Oncology and Radiotherapy最新文献

{"title":"Stereotactic body radiation therapy for lung metastases from colorectal cancer: outcomes and prognostic factors in a series of 109 patients.","authors":"Susana P F Costa, Fausto Sousa, Pedro Leite-Silva, Dora Gomes, Olga Sousa","doi":"10.5603/rpor.103527","DOIUrl":"10.5603/rpor.103527","url":null,"abstract":"<p><strong>Background: </strong>Stereotactic body radiotherapy (SBRT) has been applied in the treatment of inoperable lung metastases. We retrospectively evaluated local control (LC) and prognostic factors in patients treated with SBRT for colorectal cancer (CRC) pulmonary metastases.</p><p><strong>Materials and methods: </strong>Unicentric retrospective study of 109 patients with CRC lung metastases treated with SBRT between 2013 and 2020. The prescribed dose was 30-34 Gy in a single fraction or 40-50 Gy in 4-5 fractions. Primary end-point was LC. Secondary end-points included overall survival (OS), progression-free survival (PFS) and identification of prognostic factors that could influence survival and LC.</p><p><strong>Results: </strong>Sixty-eight patients presented rectal cancer and 41 colon cancer as primary cancer. Local PFS (LPFS) at 2 years was 81.0%. The median OS was 51 months with a 2-year OS rate of 85.8%. For PFS, 2-year rate was 30.8% and the median PFS was 11.7 months. No patient experienced grade toxicity ≥ 3. Lesion diameter was the only variable marginally significant for LPFS. Metastases located centrally were associated with a worse OS. The volume (≥ 10 cc), the administration of systemic treatment before or after SBRT and the age (≥ 70 years) were predictive factors for PFS. The volume (≥ 10 cc) and the age (≥ 70 years) were predictive factors for regional progression. Extrapulmonary disease was the most important prognostic factor for distance progression.</p><p><strong>Conclusions: </strong>SBRT proved to be a feasible, safe and effective option for the treatment of patients with CRC lung metastases, with a good LC. None of the prognostic factors studied showed a statistically significant impact on LC.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 6","pages":"700-709"},"PeriodicalIF":1.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>AURKAPS1</i>, <i>HERC2P2</i> and <i>SDHAP1</i> pseudogenes: molecular role in development and progression of head and neck squamous cell carcinomas and their diagnostic utility.","authors":"Tomasz Kolenda, Joanna Kozłowska-Masłoń, Patrycja Mantaj, Nina Grzejda, Kacper Kamiński, Maria Dziuba, Małgorzata Czarnecka, Aleksandra Leszczyńska, Paulina Poter, Kacper Guglas, Klaudia Dudek, Katarzyna Regulska, Paulina Gieremek, Beata Stanisz, Anna Florczak-Substyk, Marlena Janiczek-Polewska, Urszula Kazimierczak, Katarzyna Lamperska, Zefiryn Cybulski, Anna Teresiak","doi":"10.5603/rpor.104016","DOIUrl":"10.5603/rpor.104016","url":null,"abstract":"<p><strong>Background: </strong>Pseudogenes are epigenetic elements whose function is mostly unknown in cancer including head and neck cancers (HNSCCs). In our study we analyzed selected three pseudogenes, aurora kinase A pseudogene 1 (<i>AURKAPS1</i>), hect domain and RLD 2 pseudogene 2 (<i>HERC2P2</i>) and succinate dehydrogenase complex flavoprotein subunit A pseudogene 1 (SDHAP1), in the context of molecular function, biological role and potential utility as a biomarker in HNSCCs.</p><p><strong>Materials and methods: </strong>Based on The Cancer Genome Atlas (TCGA) data we checked potential association of pseudogenes with pathological and clinical features, survival, cellular phenotype and involvement in pathways and cellular processes, and association with patients' response to radiotherapy.</p><p><strong>Results: </strong>Only <i>AURKAPS1</i> pseudogene has significant upregulation in cancer than in normal samples and could be used as a diagnostic biomarker. Expression levels of all pseudogenes are dependent on cancer localization. <i>SDHAP1</i> are the most differentiated and associated with tumor subtypes, expressions of <i>AURKAPS1</i> do not depend on this tumor classification. Higher expression levels of <i>AURKAPS1</i>, <i>HERC2P2</i> and <i>SDHAP1</i> were associated with more aggressive phenotypes and associated with important cellular pathways and biological processes. Moreover, we observed that the expression of all pseudogenes were higher in human papilloma virus (HPV)(+) than in HPV(-) patients. Only <i>AURKAPS1</i> was associated with higher genome instability and worse response to radiotherapy. Patients with higher expression levels of <i>AURKAPS1</i> and <i>HERC2P2</i> displayed better survival.</p><p><strong>Conclusions: </strong><i>AURKAPS1</i> is a potential biomarker for HNSCC patients. This pseudogene is associated with changes in DNA repair, which should be more deeply analyzed in the future.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 6","pages":"718-731"},"PeriodicalIF":1.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912886/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143659190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncology pharmacy education for pharmacy students - should it be improved?","authors":"Julia Liwarska, Piotr Nowaczyk, Kinga Brzykcy, Mateusz Szamałek, Magdalena Waszyk-Nowaczyk","doi":"10.5603/rpor.104015","DOIUrl":"10.5603/rpor.104015","url":null,"abstract":"<p><p>Cancer remains one of the most common causes of death worldwide. This makes the process of educating medical students on the subject of oncology pharmacy all the more important. Basic teaching methods focusing on theory can prove insufficient. This paper brings together the modern didactic methods used in teaching oncology pharmacy, to the present time, and evaluates their usefulness.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 6","pages":"789-795"},"PeriodicalIF":1.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response evaluation after single-fraction hemostatic radiotherapy in advanced cancer: a prospective study.","authors":"Prashasti Sharma, Mouchumee Bhattacharyya, Partha Pratim Medhi, Apurba Kumar Kalita, Dhiru Talukdar","doi":"10.5603/rpor.104020","DOIUrl":"10.5603/rpor.104020","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy (RT) to the bleeding tumor is a potential alternative for achieving hemostasis in advanced or metastatic cancer, which is an oncologic emergency. The current study aimed to assess the effectiveness of single-fraction hemostatic RT for advanced cancer bleeding.</p><p><strong>Materials and methods: </strong>This prospective observational study included patients with complaints of bleeding from their primary or secondary cancer sites. All patients received 6 Gray single-fraction hemostatic radiotherapy using conventional technique. The primary endpoint was to evaluate Subjective and Objective responses following radiotherapy, with regard to achieving hemostasis.</p><p><strong>Results: </strong>Twenty-four patients with a median age of 45 years were included. The most common sites of bleeding were Gastrointestinal cancers (42%). The site of bleeding was the primary in 20 patients (83%), the rest had bleeding from metastatic fungating lymphadenopathy. The subjective and objective response rates to hemostatic RT were 87.5% each. The onset of response was within 24 hrs in 54.2% and at 2 weeks post-RT, there was complete control of bleeding in 45.8% of patients. The mean haemoglobin level of the study group improved by 0.9 gm/dL one week after hemostatic RT with reduced requirement of blood transfusions.</p><p><strong>Conclusions: </strong>Hemostatic RT controlled bleeding in most patients irrespective of tumour site, histology and origin of bleeding. It can improve the general condition and hemoglobin levels in cancer patients, thereby making them fit for further treatments, which will likely result in prolongation of overall survival.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 6","pages":"746-753"},"PeriodicalIF":1.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted nanodelivery systems for personalized cancer therapy.","authors":"Szymon Roszkowski, Zofia Durczyńska, Sylwia Szablewska","doi":"10.5603/rpor.103524","DOIUrl":"10.5603/rpor.103524","url":null,"abstract":"<p><p>Conventional cancer therapies such as chemotherapy face challenges such as poor tumor targeting, systemic toxicity, and drug resistance. Nanotechnology offers solutions through advanced drug delivery systems that preferentially accumulate in tumors while avoiding healthy tissues. Recent innovations have enabled the optimization of engineered nanocarriers for extended circulation and tumor localization via both passive and active targeting mechanisms. Passive accumulation exploits the leaky vasculature of tumors, whereas active strategies use ligands to selectively bind cancer cell receptors. Multifunctional nanoparticles also allow the combination of imaging, multiple therapeutic modalities and on-demand drug release within a single platform. Overall, precisely tailored nanotherapeutics that leverage unique pathophysiological traits of malignancies provide opportunities to overcome the limitations of traditional treatment regimens. This emerging field promises more effective and personalized nanomedicine approaches to detect and treat cancer. The key aspects highlighted in this review include the biological barriers associated with nanoparticles, rational design principles to optimize nanocarrier pharmacokinetics and tumor uptake, passive and active targeting strategies, multifunctionality, and reversal of multidrug resistance.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 6","pages":"776-788"},"PeriodicalIF":1.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143659003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tracing prostate cancer - the evolution of PET-CT applications.","authors":"Witold Cholewiński, Luca Camoni, Mirosława Mocydlarz-Adamcewicz, Agata Pietrzak","doi":"10.5603/rpor.102615","DOIUrl":"https://doi.org/10.5603/rpor.102615","url":null,"abstract":"<p><strong>Background: </strong>The study aimed to overview radiopharmaceuticals used for the nuclear medicine (NM) imaging of prostate cancer (Pca) since the first mentions in the literature up to recent reports, with the special focus on positron emission tomography-computed tomography (PET-CT) radiotracers.</p><p><strong>Materials and methods: </strong>We found over 3500 articles discussing the role of PET-CT in Pca patients' management published within 1990-2023. We summarized the past and present interests of the Authors when the Pca diagnostic imaging and the use of radiotracers in Pca diagnosis are considered. Eventually, we have compared the radiotracers' introduction in the literature with the United States (U.S.) Food and Drug Administration (FDA) approval timeline.</p><p><strong>Results: </strong>The most mentions by the Authors were made of the following PET-CT study compounds: 2-[¹⁸F]fluoroethyl-choline ([¹⁸F]FECh), gallium-⁶⁸-labelled prostate-specific membrane antigen using peptide-11, ([⁶⁸Ga]Ga-PSMA-11), carbon-¹¹-labelled acetic acid ([¹¹C]acetate), and the anti-1-amino-3-[¹⁸F]-fluorocyclobutane-1-carboxylic acid (<i>anti</i>-3-[¹⁸F]FACBC, Axumin®), as well as the non-tumour-specific 2-deoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG). The most recent studies analysis showed an increasing interest of the Authors not only in a relatively new Pca-specific [⁶⁸Ga]Ga-PSMA-11, but also in a widely used non-specific [¹⁸F]FDG.</p><p><strong>Conclusions: </strong>The literature analysis results lead to the conclusion that Pca remains a constant focus of the NM drug development with particularly high interest in PET-CT-dedicated radiotracers.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"627-637"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultra-low dose rate brachytherapy (uLDR-BT) in treatment of patients with unfavorable intermediate-risk group prostate cancer - retrospective analysis.","authors":"Adam Kluska, Artur Chyrek, Wojciech Maria Burchardt, Marcin Włodarczyk, Grzegorz Bielęda, Adam Chicheł","doi":"10.5603/rpor.103135","DOIUrl":"https://doi.org/10.5603/rpor.103135","url":null,"abstract":"<p><strong>Background: </strong>Treatment with sole ultra-low dose rate brachytherapy (uLDR-BT) for unfavorable intermediate risk factor (IUR) group prostate cancer patients is not recommended by guidelines due to the lack of strong evidence of its effectiveness. However, there were numerous patients treated with good results with this method in older trials. Purpose of this work was to retrospectively asses effectiveness of uLDR-BT in IUR group treated in our department.</p><p><strong>Materials and methods: </strong>We performed retrospective analysis of 39 IUR prostate cancer patients treated in our department with uLDR-BT between 2015-2019. All Patients had confirmed prostate cancer in biopsy and had local staging assessed with digital rectal examination and either transrectal ultrasound (TRUS) or magnetic resonance imaging (MRI) before treatment. Treatment was performed using ¹²⁵I seeds, and the dose prescribed to the clinical target volume was 145 Gy. After treatment, all patients were followed in our outpatient ambulatory one month after the procedure and every 3-6 months later on. Toxicity was assessed using the International Prostate Symptom Score (IPSS) and Radiation Therapy Oncology Group (RTOG) scales.</p><p><strong>Results: </strong>The median follow-up was 56,3 months [interquartile range (IQR): 36.9-73.4]. The mean nadir prostate-specific antigen (PSA) was 0.20 ng/mL (range 0.001-1.7). The actuarial 5-year biochemical failure-free survival (BFFS) was 87.02%. There was no statistically significant difference in BFFS between groups with antigen deprivation therapy (ADT) and without (p = 0.439). Analysis also showed no impact on BFFS of each intermediate group risk factors: initial PSA (iPSA) (p = 0.595). Gleason (p = 0.671) and Tumor stage (p = 0.694). There were no statistically significant differences in BFFS depending on number of those factors (p = 0.330).</p><p><strong>Conclusion: </strong>The uLDR-BT may be an effective option for selected IUR prostate cancer patients.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"600-605"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of degree of acute radiation dermatitis (RD) with skin dose distribution in head and neck squamous cell carcinoma patients treated with definitive concurrent chemoradiation.","authors":"Sattwik Basu, Subrata Chatterjee, Kaustav Chatterjee, Sattama Samanta, Solanki Saha, Sk Toslim Hossain, Pritha Mondal, Shyamal Biswas","doi":"10.5603/rpor.102824","DOIUrl":"https://doi.org/10.5603/rpor.102824","url":null,"abstract":"<p><strong>Background: </strong>Radiation dermatitis (RD) or skin toxicity is one of the most common acute side effects of radiation in head and neck cancer patients. This study aims to correlate the pattern of volumetric-modulated arc therapy (VMAT) dose distribution to the skin with the grades of RD.</p><p><strong>Materials and methods: </strong>80 plans of histopathologically proven squamous cell carcinoma head and neck patients already treated with definitive concurrent chemoradiation [66-70 Gy in 33-35# or 66 Gy in 30# in simultaneous integrated boost (SIB), with concurrent Cisplatin 100 mg/m² 3 weekly] at our institution between November 2022 and November 2023 were retrieved from our digital archives. For each plan, 1 ring structure was created 3mm below the external skin surface, and the parameters V₄₀, V₅₀, V₆₀ and D_max were collected from the same. These parameters were correlated with grades of RD as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0. The statistical analysis was done using MedCalc software version 22.021.</p><p><strong>Results: </strong>The incidence of G2/G3 RD was 52.5%, and its incidence was significantly correlated with all of the four parameters. Statistically significant (p < 0.001) dosimetric predictive accuracy was provided by 71.66 cc, 29.98 cc and 7.624 cc of the 3mm skin ring V_40, V₅₀ and V₆₀, respectively.</p><p><strong>Conclusion: </strong>The dose distribution pattern to a skin layer stationed 3mm below the surface may help predict the development of severe RD in head and neck cancer patients receiving concurrent chemoradiation.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"579-587"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetric verification of point doses for I-125 implants designed by different manufacturers in prostate brachytherapy.","authors":"Agata Lewandowska, Dorota Borowicz, Grzegorz Bielęda, Oliwia Nowotka, Maksymilian Kazior, Justyna Krupka, Marek Kanikowski, Maciej Kozak","doi":"10.5603/rpor.102819","DOIUrl":"https://doi.org/10.5603/rpor.102819","url":null,"abstract":"<p><strong>Background: </strong>The purpose of this study is to determine the effect of the type of I-125 radioactive source on dose distribution in the planning process of ultra-low dose rate (uLDR) prostate brachytherapy.</p><p><strong>Material and methods: </strong>7 patients who had undergone brachytherapy in our center were included in the study. Dose in five geometrical points were analyzed for 12 types of implants that are available on the market. The plans were originally calculated for S17plus implant model (Eckert & Ziegler Medical). Point dose calculations were performed using RadCalc (LAP) software.</p><p><strong>Results: </strong>The differences in doses for individual points were significant. The largest differences were observed at the point located in the center of the patients' urethra and between BestMedical 2301 (highest doses for each point) and IsoStar (lowest doses) implants.</p><p><strong>Conclusions: </strong>The choice of implant manufacturer strongly influences what dose distribution will be obtained for the prostate. It is possible to obtain satisfactory plans that meet the dosimetric criteria for each type of implant, but the positioning of each source will vary significantly.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"588-599"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reirradiation of gliomas with hypofractionated stereotactic radiotherapy: efficacy and tolerance analysis at a single center.","authors":"Mercedes López González, Raquel Ciervide, Ovidio Hernando Requejo, Ángel Montero Luis, Beatriz Álvarez Rodriguez, Emilio Sánchez Saugar, Leyre Alonso Iracheta, Xin Chen, Mariola Garcia-Aranda, Daniel Zucca, Jeannette Valero, Rosa Alonso, Pedro Fernández-Letón, Carmen Rubio","doi":"10.5603/rpor.102820","DOIUrl":"https://doi.org/10.5603/rpor.102820","url":null,"abstract":"<p><strong>Background: </strong>Recurrent high-grade gliomas present a therapeutic challenge. Repeat surgery, re-irradiation, and systemic therapy have been explored, with re-irradiation requiring precise tumor relapse delineation and advanced dosimetric techniques. This study aims to evaluate the effectiveness and tolerability of re-irradiation using Hypofractionated Stereotactic Radiation (HFSRT) schedules.</p><p><strong>Materials and methods: </strong>In a retrospective analysis from 2011 to 2021, 52 adult patients with recurrent high-grade gliomas were examined, including 42.3% with glioblastoma, 32.5% with grade 3 gliomas, and 25% with grade 2 gliomas as initial diagnosis. All received prior radiotherapy at doses ranging from 54-60 Gy, with a median time to tumor relapse of 19.8 months. Salvage surgery was performed in 42.3% of cases, with a median interval of 22.45 months between radiation courses. Re-irradiation doses were 30 Gy in 5 fractions for 54% and 40 Gy in 10 fractions for 46%. Concurrent systemic treatments included temozolomide (30.8%), nevacizumab (27%), or none (35%).</p><p><strong>Results: </strong>In-field and out-field tumor progression occurred in 65.4% and 25% of patients, with median times to local and distant progression of 5.17 and 4.57 months. Median overall survival (OS) from re-irradiation was 12 months. Univariate analysis showed a trend favoring 30 Gy in 5 fractions for disease progression-free survival (DPFS). Treatment was generally well-tolerated, with only 5.7% experiencing acute Grade-3 toxicity, and symptomatic radionecrosis occurred in 2 patients.</p><p><strong>Conclusion: </strong>Re-irradiation using HFSRT for recurrent high-grade gliomas is viable and well-tolerated, demonstrating survival rates comparable to existing literature. These findings underscore the potential of HFSRT in managing recurrent high-grade gliomas.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"566-578"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}